Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | BHMT | Q93088 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11155757 | 0.97 | LMNA (0.72) | LMNAKMT2AHSD17B10TDP1BHMT | |
| SCHEMBL10482292 | 0.89 | LMNA (0.62) | LMNAKMT2AHSD17B10TDP1BHMT | |
| SCHEMBL10482221 | 0.89 | LMNA (0.62) | LMNAKMT2AHSD17B10TDP1BHMT | |
| E388 SCHEMBL28696 | 0.87 | LMNA (1.00) | LMNAKMT2AHSD17B10TDP1BHMT | |
| E388 SCHEMBL28962323 | 0.87 | LMNA (1.00) | LMNAKMT2AHSD17B10TDP1BHMT | |
| E388 SCHEMBL341724 | 0.84 | LMNA (0.93) | LMNAKMT2AHSD17B10TDP1BHMT | |
| E388 SCHEMBL21494504 | 0.84 | LMNA (0.93) | LMNAKMT2AHSD17B10TDP1BHMT | |
| E388 SCHEMBL9715444 | 0.84 | LMNA (0.93) | LMNAKMT2AHSD17B10TDP1BHMT | |
| E388 SCHEMBL9715431 | 0.84 | LMNA (0.93) | LMNAKMT2AHSD17B10TDP1BHMT | |
| E388 SCHEMBL11415832 | 0.84 | LMNA (0.93) | LMNAKMT2AHSD17B10TDP1BHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419551-B2 | Mediation of in vivo analyte signal degradation | SENSEONICS, INCORPORATED (US) | 2025-09-23 | — | — | US | claimed |
| EP-3965657-B1 | MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION | SENSEONICS INC (US) | 2025-03-05 | — | — | EP | claimed |
| CN-115300637-A | Chalcogen hybrid bond bridged dimer prodrug, self-assembled nanoparticles thereof, preparation method and application | 沈阳药科大学 | 2022-11-08 | — | — | CN | claimed |
| JP-1226811-A | — | — | None | — | — | JP | disclosed |
| US-20260008997-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | GENENTECH, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-2970875-B2 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-12419551-B2 | Mediation of in vivo analyte signal degradation | SENSEONICS, INCORPORATED (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3965657-B1 | MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION | SENSEONICS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-115300637-B | Chalcogen hybrid bond bridged dimer prodrug, self-assembled nanoparticle thereof, preparation method and application | 沈阳药科大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-115300637-A | Chalcogen hybrid bond bridged dimer prodrug, self-assembled nanoparticles thereof, preparation method and application | 沈阳药科大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-114703244-A | Method for reducing trisulfide bonds during recombinant production of polypeptides | 豪夫迈·罗氏有限公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-0327306-A2 | Leukotriene B4 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-08-09 | — | — | EP | disclosed |
| US-4730005-A | DITHIA-ALKANEDIOIC ACIDS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0168902-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1987-09-30 | — | — | EP | disclosed |
| EP-0153009-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1987-01-07 | — | — | EP | disclosed |
| US-4623535-A | ANTIASTHMA | SMITHKLINE BECKMAN CORPORATION (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0168902-A1 | Leukotriene antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-01-22 | — | — | EP | disclosed |
| EP-0153009-A1 | Leukotriene antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1985-08-28 | — | — | EP | disclosed |
| US-4523024-A | STABILIZERS FOR ORGANIC MATERIALS SENSITIVE TO HEAT, LIGHT, AND/OR OXIDATIVE FACTORS | KURARAY CO., LTD. (JP) | 1985-06-11 | — | — | US | disclosed |
| EP-0113042-A2 | 3,4-Dihydro-2H-benzopyran derivatives, a method of producing them, a method of using them as stabilizers for organic materials, and organic compositions containing such stabilizers | KURARAY CO., LTD. (JP) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419551-B2 | Mediation of in vivo analyte signal degradation | SLC2A1, TXN2, SLC2A8 | LMNA 4443/4885KMT2A 4370/4885HSD17B10 1692/4885 |
| US-20260008997-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | CD99, BHMT, PROC | LMNA 1603/4885KMT2A 3095/4885HSD17B10 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.